Fresh analysis reveals that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle plans.
Published data in a prominent health publication points out that while overweight people often shed about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals buying such drugs need to be informed of the potential of quick weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to pre-treatment mass in about a year and a half.
Analyzing Therapies
The analysis, which looked at dozens of trials involving thousands of patients, contrasted the effects of the injectable medications with conventional dieting.
Researchers point out that people who lose weight through diet and exercise typically see a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Doctors suggest the mechanism of the drugs explains the heightened weight return.
These medications imitate a natural hormone called GLP-1, which moderates appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication results in hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines advise the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Many experts say that, given the high risk of relapse, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," similar to managing diseases like diabetes.
User Accounts
Individuals who have come off the jabs explain a sudden resurgence of hunger.
"I experienced a switch activating and you become ravenous," recalled an individual.
This difficulty is worsened if patients have not established permanent lifestyle or habit modifications during therapy.
Growing Adoption
Recent estimates show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is higher among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on integrated lifestyle support.
